Biotech Stocks Soar on Positive Cancer Study Results
ImmunoGen's drug, Elahere, lowered the risk of disease progression or death by 35% in a specific group of patients with ovarian cancer, while Day One Biopharmaceuticals' drug, Tovarafenib, showed a 67% response rate in pediatric brain tumors. Replimune's skin cancer treatment showed a 37% response rate in melanoma patients. Gilead Sciences and Arcus Biosciences' lung cancer treatment showed a median of 9.3 to 9.9 months before worsening.